Next Article in Journal
Understanding the Influence of the Head Coach on Soccer Training Drills—An 8 Season Analysis
Next Article in Special Issue
Ibrutinib Could Suppress CA-125 in Ovarian Cancer: A Hypothesis
Previous Article in Journal
An Energy Saving Road Sweeper Using Deep Vision for Garbage Detection
Previous Article in Special Issue
Integration of Molecular Docking and In Vitro Studies: A Powerful Approach for Drug Discovery in Breast Cancer
 
 
Article
Peer-Review Record

Improved Anticancer Activity of the Malloapelta B-Nanoliposomal Complex against Lung Carcinoma

Appl. Sci. 2020, 10(22), 8148; https://doi.org/10.3390/app10228148
by Thi Thao Do 1,2,*, Thi Nga Nguyen 1, Thi Phuong Do 1, Thi Cuc Nguyen 1, Ha Phuong Trieu 1, Phuong Thi Thu Vu 1 and Tuan Anh Hoang Le 3
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Reviewer 3: Anonymous
Reviewer 4: Anonymous
Appl. Sci. 2020, 10(22), 8148; https://doi.org/10.3390/app10228148
Submission received: 17 October 2020 / Revised: 6 November 2020 / Accepted: 14 November 2020 / Published: 17 November 2020
(This article belongs to the Special Issue Anticancer Drugs Activity and Underlying Mechanisms)

Round 1

Reviewer 1 Report

Accept with english corrections

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

The authors report their work on the anticancer activity of the malloapelta B 3 nanoliposomal complex against lung carcinoma. This research suggested that malB-nanoliposomes enhanced the inhibition of colony forming activity and increased caspase 3 activity in A549 cells. The nanoliposomal formulations also showed potential to inhibit tumor growth and prolong survival of tumor-bearing mice compared with the unloaded drug. For further publication, some suggestions are shown below.

  1. Figure 2A provides cell viability results of malB nanoliposome compared to the blank liposome. Please clearly symbolize the statistical significance.
  2. In animal studies, there was no significant difference in the survival rate of mice treated with malB-nanoliposomes compared with the control group or blank liposome. Therefore, the conclusion that "malB-nanoliposomes prolong the survival of tumor-bearing mice" should be deleted.
  3. Why did the author treat tumor-bearing mice by ip injection? Is this treatment route suitable for lung cancer?
  4. In this manuscript, the author mentioned that liposome encapsulation can reduce drug toxicity. Please provide the weight of mice in each treatment.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 3 Report

This manuscript gives an excellent account on the synthesis, characterisation and extended in vitro and in vivo investigation of mal-B nanoliposomes on lung cancer models. The authors provide evidence for the enhanced activity of the encapsulated complex compared to the free drug molecule. In the introduction a few sentences should be devoted to the anticancer enones as mal-B also contains an enone side chain probably contributing to the activity of this molecule. The chemical structure is also worth to be presented in an inserted Figure. 

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 4 Report

The manuscript entitle: Improved anticancer activity of the malloapelta B nanoliposomal complex against lung carcinoma is interested and good prepared. However, some figures are unreadable and it should be color. The scale on X-axis are too small, the unit should be in only one place.

Author Response

Please see the attachement.

Author Response File: Author Response.docx

Round 2

Reviewer 4 Report

I recommend to publish

Back to TopTop